EMA/CO Combination Chemotheraphy in Gestational Trophoblastic Neoplasia: Update of Our Results

OBJECTIVE: In this study, we aimed updating our experience about the treatment success of EMA-CO (etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine) chemotherapy in high-risk gestational trophoblastic neoplasia (GTN). MATERIAL AND METHOD: Patients were scored according to FIGO’...

Full description

Saved in:
Bibliographic Details
Main Authors: Tolga Taşçı, Işın Üreyen, Günsu Kimyon, Alper Karalök, Sevgi Koç, M. Faruk Köse, Gökhan Tulunay, Taner Turan
Format: Article
Language:English
Published: Medical Network 2015-08-01
Series:Gynecology Obstetrics & Reproductive Medicine
Subjects:
Online Access:https://gorm.com.tr/index.php/GORM/article/view/25
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823857291311448064
author Tolga Taşçı
Işın Üreyen
Günsu Kimyon
Alper Karalök
Sevgi Koç
M. Faruk Köse
Gökhan Tulunay
Taner Turan
author_facet Tolga Taşçı
Işın Üreyen
Günsu Kimyon
Alper Karalök
Sevgi Koç
M. Faruk Köse
Gökhan Tulunay
Taner Turan
author_sort Tolga Taşçı
collection DOAJ
description OBJECTIVE: In this study, we aimed updating our experience about the treatment success of EMA-CO (etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine) chemotherapy in high-risk gestational trophoblastic neoplasia (GTN). MATERIAL AND METHOD: Patients were scored according to FIGO’s modified WHO system. Risk scoring of patients before 2000 was remade by using this system. Thirty-nine patients who were treated with EMA-CO between 1992 and 2013 because of high risk GTN or the resistance to single agent methotrexate and MAC III chemotherapy combinations were evaluated retrospectively. Adjuvant surgery and radiotherapy were used in selected patients. Response and effects of the prognostic factors to the response rate were analyzed. RESULTS: Median follow-up time of the patients was 74.8 months (range, 1-203). Complete clinical response was obtained in 36 (92.3%) patients with only EMA-CO or EMA-CO and surgery. The response rate of treatment was 91.3% (n:21/23) in patients taking primary EMA-CO, 93.8% (n:15/16) in patients taking secondary EMA/CO chemotherapy. Resistance to the EMA-CO treatment developed in 6 (15.3%) patients and 3 of the patients with drug resistance died. During the follow-up time disease recurred in 3 (7.7%) patients. When the antecedent pregnancy was term pregnancy or the histopathological diagnosis was choriocarcinoma or when there was liver metastasis, the treatment success decreased. The effects of tumor dimension and the presence of metastasis tended to be statistically significant in determining the resistance to therapy. CONCLUSION: EMA-CO regimen is highly effective for treatment of high-risk GTN. Because of the differences in many studies, risk factors for predicting the success of the treatment are not clear.
format Article
id doaj-art-8d4ccba4f3af4c3ab3422ae22ff4d6c2
institution Kabale University
issn 1300-4751
2602-4918
language English
publishDate 2015-08-01
publisher Medical Network
record_format Article
series Gynecology Obstetrics & Reproductive Medicine
spelling doaj-art-8d4ccba4f3af4c3ab3422ae22ff4d6c22025-02-11T21:25:51ZengMedical NetworkGynecology Obstetrics & Reproductive Medicine1300-47512602-49182015-08-0121220EMA/CO Combination Chemotheraphy in Gestational Trophoblastic Neoplasia: Update of Our ResultsTolga Taşçı0Işın Üreyen1Günsu Kimyon2Alper Karalök3Sevgi Koç4M. Faruk Köse5Gökhan Tulunay6Taner Turan7Etlik Zübeyde Hanım Women’s Health Teaching and Research Hospital Gynecologic Oncology Division, AnkaraEtlik Zübeyde Hanım Women’s Health Teaching and Research Hospital Gynecologic Oncology Division, AnkaraEtlik Zübeyde Hanım Women’s Health Teaching and Research Hospital Gynecologic Oncology Division, AnkaraEtlik Zübeyde Hanım Women’s Health Teaching and Research Hospital Gynecologic Oncology Division, AnkaraEtlik Zübeyde Hanım Women’s Health Teaching and Research Hospital Gynecologic Oncology Division, AnkaraBahçeşehir University School of Medicine Department of Obstetrics and Gynecology, IstanbulEtlik Zübeyde Hanım Women’s Health Teaching and Research Hospital Gynecologic Oncology Division, AnkaraEtlik Zübeyde Hanım Women’s Health Teaching and Research Hospital Gynecologic Oncology Division, Ankara OBJECTIVE: In this study, we aimed updating our experience about the treatment success of EMA-CO (etoposide, methotrexate, actinomycin-D, cyclophosphamide, vincristine) chemotherapy in high-risk gestational trophoblastic neoplasia (GTN). MATERIAL AND METHOD: Patients were scored according to FIGO’s modified WHO system. Risk scoring of patients before 2000 was remade by using this system. Thirty-nine patients who were treated with EMA-CO between 1992 and 2013 because of high risk GTN or the resistance to single agent methotrexate and MAC III chemotherapy combinations were evaluated retrospectively. Adjuvant surgery and radiotherapy were used in selected patients. Response and effects of the prognostic factors to the response rate were analyzed. RESULTS: Median follow-up time of the patients was 74.8 months (range, 1-203). Complete clinical response was obtained in 36 (92.3%) patients with only EMA-CO or EMA-CO and surgery. The response rate of treatment was 91.3% (n:21/23) in patients taking primary EMA-CO, 93.8% (n:15/16) in patients taking secondary EMA/CO chemotherapy. Resistance to the EMA-CO treatment developed in 6 (15.3%) patients and 3 of the patients with drug resistance died. During the follow-up time disease recurred in 3 (7.7%) patients. When the antecedent pregnancy was term pregnancy or the histopathological diagnosis was choriocarcinoma or when there was liver metastasis, the treatment success decreased. The effects of tumor dimension and the presence of metastasis tended to be statistically significant in determining the resistance to therapy. CONCLUSION: EMA-CO regimen is highly effective for treatment of high-risk GTN. Because of the differences in many studies, risk factors for predicting the success of the treatment are not clear. https://gorm.com.tr/index.php/GORM/article/view/25EMA/COGestational trophoblastic neoplasiaPrognostic factors
spellingShingle Tolga Taşçı
Işın Üreyen
Günsu Kimyon
Alper Karalök
Sevgi Koç
M. Faruk Köse
Gökhan Tulunay
Taner Turan
EMA/CO Combination Chemotheraphy in Gestational Trophoblastic Neoplasia: Update of Our Results
Gynecology Obstetrics & Reproductive Medicine
EMA/CO
Gestational trophoblastic neoplasia
Prognostic factors
title EMA/CO Combination Chemotheraphy in Gestational Trophoblastic Neoplasia: Update of Our Results
title_full EMA/CO Combination Chemotheraphy in Gestational Trophoblastic Neoplasia: Update of Our Results
title_fullStr EMA/CO Combination Chemotheraphy in Gestational Trophoblastic Neoplasia: Update of Our Results
title_full_unstemmed EMA/CO Combination Chemotheraphy in Gestational Trophoblastic Neoplasia: Update of Our Results
title_short EMA/CO Combination Chemotheraphy in Gestational Trophoblastic Neoplasia: Update of Our Results
title_sort ema co combination chemotheraphy in gestational trophoblastic neoplasia update of our results
topic EMA/CO
Gestational trophoblastic neoplasia
Prognostic factors
url https://gorm.com.tr/index.php/GORM/article/view/25
work_keys_str_mv AT tolgatascı emacocombinationchemotheraphyingestationaltrophoblasticneoplasiaupdateofourresults
AT isınureyen emacocombinationchemotheraphyingestationaltrophoblasticneoplasiaupdateofourresults
AT gunsukimyon emacocombinationchemotheraphyingestationaltrophoblasticneoplasiaupdateofourresults
AT alperkaralok emacocombinationchemotheraphyingestationaltrophoblasticneoplasiaupdateofourresults
AT sevgikoc emacocombinationchemotheraphyingestationaltrophoblasticneoplasiaupdateofourresults
AT mfarukkose emacocombinationchemotheraphyingestationaltrophoblasticneoplasiaupdateofourresults
AT gokhantulunay emacocombinationchemotheraphyingestationaltrophoblasticneoplasiaupdateofourresults
AT tanerturan emacocombinationchemotheraphyingestationaltrophoblasticneoplasiaupdateofourresults